real-time news and commentary for investors
Sunday, Oct 27
Merck may test vicriviroc as cancer treatment: Citi
- Is Merck's (MRK) vicriviroc about to get a second lease on life as a potential treatment for cancer? Citi apparently thinks so.
- Development of vicriviroc as a treatment for HIV was halted several years ago after it missed primary endpoints in clinical testing, but new research suggests CCR5 inhibitors like vicriviroc may have a role in reducing the spread of cancer cells and could be paired with cancer immunotherapies in clinical trials.
- "Citi [expects] vicriviroc to re-enter clinical testing in combination with cancer immunotherapy as MRK explores its potential across multiple tumor types, including melanoma, colorectal, breast, prostate and liver cancer," Reuters says.
- For its part, MRK says it "has not disclosed" such plans.
- Another CCR5 inhibitor: Pfizer's (PFE) Selzentry.